Clinical Trials Collective Safety Topical 
Puff Puff Post
MARCH 10, 2020
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.
Puff Puff Post
MARCH 10, 2020
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 21, 2021
RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. The company’s analysis of the collected data yielded several insights. How to Use the Data.
The Blunt Truth
AUGUST 13, 2019
On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The FDA is collecting data to fill these gaps. The public hearing attracted over 100 speakers and 2000 participants. First, Sens.
The Cannigma
JULY 1, 2022
There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible.
The Cannigma
DECEMBER 12, 2022
Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.
Puff Puff Post
NOVEMBER 5, 2019
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.
Expert insights. Personalized for you.
84 
Let's personalize your content